Lee Ainslie's CNTA Position Overview
Lee Ainslie (via Maverick Capital LTD) currently holds 1.64 M shares of Centessa Pharmaceuticals plc (CNTA) worth $41.11 M, representing 0.44% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Lee Ainslie has initiated a new position in CNTA, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Lee Ainslie's Centessa Pharmaceuticals plc (CNTA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Centessa Pharmaceuticals plc (CNTA) Trades by Lee Ainslie
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +1.64 M | New Buy | 1.64 M | $25.01 |
Lee Ainslie's Centessa Pharmaceuticals plc Investment FAQs
Lee Ainslie first purchased Centessa Pharmaceuticals plc (CNTA) in Q4 2025, acquiring 1,643,724 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Lee Ainslie has held Centessa Pharmaceuticals plc (CNTA) for 1 quarters since Q4 2025.
Lee Ainslie's largest addition to Centessa Pharmaceuticals plc (CNTA) was in Q4 2025, adding 1,643,724 shares worth $41.11 M.
According to the latest 13F filing for Q4 2025, Lee Ainslie's firm, Maverick Capital LTD, owns 1,643,724 shares of Centessa Pharmaceuticals plc (CNTA), valued at approximately $41.11 M.
As of the Q4 2025 filing, Centessa Pharmaceuticals plc (CNTA) represents approximately 0.44% of Lee Ainslie's publicly disclosed stock portfolio, making it one of their key holdings.
Lee Ainslie's peak holding in Centessa Pharmaceuticals plc (CNTA) was 1,643,724 shares, as reported at the end of Q4 2025.